Copenhagen, Denmark—10 August 2025 – FluoGuide A/S has released highlights from its live-recorded Redeye interview (English) and Q&A session (Danish) on 8 August 2025. Both sessions focused on the company’s partner-driven strategy to accelerate the commercialization of FG001 and broaden its market potential.
Partner Collaborations Driving Surgical Integration
FluoGuide is collaborating with global leaders in surgical technologies, including Intuitive Surgical, Olympus, and SurgVision (Bracco Group). These non-exclusive agreements aim to integrate FG001—its fluorescence-guided surgery product—into established surgical platforms. The goal: reduce clinical and regulatory risk, speed adoption, and expand FG001’s use across numerous cancer indications.
Immediate and Future Strategic Goals
In the short term, FluoGuide is strengthening partnerships to support FG001’s market entry and ensure smooth integration into surgical workflows. Looking into 2025–2026, it plans to:
- Deepen alliances with top surgical platform providers.
- De-risk clinical and regulatory pathways.
- Expand FG001 applications across cancer types.
- Enhance the product’s combined value alongside advanced surgical tools.
“The focus is clear – we are building a strong foundation for FG001’s commercial success, enabling faster, more cost-effective, and broader market penetration,” said Morten Albrechtsen, CEO of FluoGuide.
Leave a Comment